Key antidepressant from AZ/Targacept fails trial

The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's ($AZN) struggling R&D operation another stinging setback and walloping Targacept ($TRGT) with a meltdown in its share value this morning. Report

Suggested Articles

With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections.

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.